.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,932,560

« Back to Dashboard

Details for Patent: 5,932,560

Title: Treatment of conditions and disease
Abstract:A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
Inventor(s): Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel S. (Toronto, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:Jun 05, 1995
Application Number:08/461,124
Claims:1. A method of inhibiting enzymatic production of prostaglandin synthesis in a mammal suffering from macrophage blockage, the method comprising administering to the mammal a therapeutically effective amount of an agent to inhibit enzymatic production of prostaglandin synthesis and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and non-toxic salts thereof and combination thereof sufficient to facilitate transportation and penetration of the agent through tissue at a site to be treated through cell membranes into individual cells to be treated, wherein said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10 mg and wherein the form of hyaluronic acid has a molecular weight less than 750,000 daltons but greater than 150,000 daltons and said agent is acetylsalicylic acid.

2. A dosage amount of a pharmaceutical composition suitable for enhancing prostaglandin synthesis inhibition in a human who will benefit from the inhibition by the administration of a therapeutically effective amount of an agent and an amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and non-toxic salts thereof and combinations thereof sufficient to facilitate the penetration of the agent to the site to be treated through the tissue and through cell membranes into the individual cells to be treated wherein said amount of the form of hyaluronic acid is sufficient to provide a dosage between 10 mg of the form of the hyaluronic acid and 1000 mg of the form of hyaluronic acid and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons but greater than 150,000 daltons, and said agent is acetylsalicylic acid.

3. The dosage amount of claim 2 wherein the form of hyaluronic acid is sodium hyaluronate.

4. A method of administering an effective dosage amount of a pharmaceutical composition comprising a therapeutically effective amount of acetylsalicylic acid with a form of hyaluronic acid selected from the group consisting of hyaluronic acid and non-toxic salts thereof and combinations thereof sufficient to facilitate the acetylsalicylic acid penetration through the tissue, at the site to be treated, through the cell membranes into the individual cells to be treated, wherein said amount of the form of hyaluronic acid is sufficient to provide a dosage between 200 mg and 1000 mg of the form of hyaluronic acid and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons but greater than 150,000 daltons.

5. The method of claim 4 wherein the form of hyaluronic acid is sodium hyaluronate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc